On a Monday in early January, the American Academy of Pediatrics offered something it had not offered in fifteen years: a new framework for treating obesity in children, reaching down to age two and up through adolescence. It asks clinicians to see excess weight less as a failure of willpower and more as a chronic condition shaped by food access, movement, and the care available to a family. The guidelines extend into medicine and surgery for the older and more severely affected, a shift that acknowledges how many young lives are touched by a disease that has quietly become one of the country'
AAP Guidelines Now Recommend Weight-Loss Drugs and Surgery for Some Children With Obesity
Over 14.4 million U.S. children have obesity and face elevated risks of type 2 diabetes, sleep apnea, heart disease, and other conditions.
Drugs from 12, surgery from 13 — and a 15-year wait for new guidance
Mark
Why is this a big deal? Doctors already treated childhood obesity.
Mimi
Because the last guidelines were 15 years ago, and these now put medication and surgery on the table for children, not just lifestyle advice.
Mark
Where are the age lines?
Mimi
Drugs from 12 up, surgery from 13 for severe obesity. Under 12, the academy says there isn't enough evidence to recommend drugs just for obesity.
Luke
Worth noting that's a statement about evidence, not a verdict that drugs don't work in younger kids. The gap is unstudied, not disproven.
Mark
And the results for Wegovy?
Mimi
Adolescents lost an average of 14.7% of body weight with counseling, while the placebo group gained 2.7%.
Luke
That's one trial, and the over-40% BMI reduction figure comes from one researcher speaking to NBC. The 70-pound loss is one participant's account. Strong signals, but not the whole picture.
Mark
What about long-term effects?
Luke
The source doesn't say. Nothing here covers what happens after stopping, or years out.
Mimi
And the supply problem is real. Wegovy is already listed in shortage.
Mark
What's missing from the guidelines?
Mimi
Prevention. The academy says a separate statement is coming.
O Pulso
- The academy's first treatment guidance in fifteen years lands on a population of over 14.4 million American children who already live with obesity.
- Weight-loss medications now enter the conversation for children as young as twelve, a line that clinicians and families must navigate with care.
- Bariatric surgery is raised as an option for adolescents thirteen and older with severe obesity, pressing hard on questions of readiness and consequence.
- Demand for Wegovy has pushed the drug into FDA-listed shortage, so a prescribing expansion meets a supply that is already strained.
- Children under twelve are left without an evidence-backed drug pathway, and the promised prevention statement remains unwritten.
On a Monday in early January, the American Academy of Pediatrics offered something it had not offered in fifteen years: a new framework for treating obesity in children, reaching down to age two and up through adolescence. It asks clinicians to see excess weight less as a failure of willpower and more as a chronic condition shaped by food access, movement, and the care available to a family. The guidelines extend into medicine and surgery for the older and more severely affected, a shift that acknowledges how many young lives are touched by a disease that has quietly become one of the country's most widespread childhood burdens. Prevention, the older and perhaps more fundamental question, is being deferred to a document still to come.
On Monday, the American Academy of Pediatrics released its first obesity treatment guidelines in fifteen years, and they reach further than many families or doctors might have expected. For children, the guidance now endorses weight-loss medication for some and surgery for others. It covers children from age two upward, though it leaves out toddlers because excess fat is hard to define and measure at that age. The academy frames obesity as a chronic disease shaped by access to nutritious food, physical activity, and healthcare, and it has chosen to focus on treatment now, saving prevention for a later statement.
The numbers behind the decision are large. The CDC counts more than 14.4 million American children with obesity, a condition linked to type 2 diabetes, sleep apnea, heart disease, asthma, and joint trouble. The new guidelines call for yearly screening of children six and older, using tools such as BMI checks and motivational conversations. Treatment is tiered by age. Drugs are recommended from age twelve alongside lifestyle therapy, while children under twelve lack enough evidence to receive medication for obesity alone. Surgery should be considered for teenagers thirteen and older with severe obesity, and one study found that adolescents who underwent it saw their BMI fall by 29 percent.
Several medications now have a place in this picture. Wegovy, an injectable, is approved for adolescents, though the FDA lists it in shortage because demand has outpaced supply. Saxenda, Qsymia, and orlistat are also approved for older children. Some drugs are used off-label, including metformin, which the AAP's own 2021 report found was the most commonly prescribed weight-loss drug among young people. The strongest evidence comes from a trial in which adolescents on Wegovy with counseling lost an average of 14.7 percent of their body weight, while those on placebo gained 2.7 percent. One participant told NBC she lost 70 pounds during the study.
Two questions now hang over the guidance. The first is when the academy's prevention statement will arrive. The second is whether a rush of new prescriptions will deepen a shortage that is already keeping some children from the medicine their doctors may now recommend.
On Monday, the American Academy of Pediatrics published its first guidelines in 15 years for treating obesity in children, and they go further than many families and doctors might expect: they endorse weight-loss medication for some young patients and bariatric surgery for others.
The guidelines cover children aged two and older. Those under two were left out because, the academy says, it is hard to practically define and measure excess adiposity at that age. The document treats obesity as a chronic disease tied to factors such as limited access to nutritious food, physical activity and healthcare. It also focuses on treatment rather than prevention. The academy says prevention will be addressed in another forthcoming policy statement.
The scale of the problem is large. According to the CDC, more than 14.4 million children in the U.S. have obesity, and they face a higher risk of type 2 diabetes, sleep apnea, gallbladder disease, heart disease, asthma, and joint and bone problems. The CDC defines overweight in children and teens as a BMI at or above the 85th percentile and below the 95th. Obesity begins at the 95th percentile. In the CDC's example, a 10-year-old boy with a BMI of 21 is at the 85th percentile and overweight, while one with a BMI of 23 is at the 95th and considered obese. Under the new guidelines, children six and older should be screened for obesity every year, through methods such as BMI checks and motivational interviews.
The treatment recommendations are tiered by age. Weight-loss drugs are recommended for children 12 and older, alongside behavioral and lifestyle therapy. For children under 12, the academy found too little evidence to recommend drugs solely to treat obesity. For those 13 and older with severe obesity, the guidelines say surgery should be considered. One study found that adolescents who had bariatric surgery, a group of procedures on the stomach or intestines, saw their BMI fall by 29%. Dr. Sandra Hassink, an author of the guidelines and vice chair of the AAP's Clinical Practice Guideline Subcommittee on Obesity, said in a news release that the aim is to help patients make sustainable changes in lifestyle, behavior or environment.
Several FDA-approved drugs are available for children 12 and up. Novo Nordisk's Wegovy (semaglutide), an injectable, is approved for adolescents with obesity, though the FDA now lists it as being in shortage because of demand. Saxenda (liraglutide), a daily injection, is approved for obesity management at 12 and older. In June 2022 the FDA approved Qsymia, an extended-release capsule of phentermine and topiramate, for chronic weight management in patients 12 and older with obesity. Orlistat, sold as Alli and Xenical, is a daily capsule approved for ages 12 and up. The academy says GLP-1 receptor agonists such as semaglutide, exenatide, liraglutide and dulaglutide reduce hunger by slowing gastric emptying and acting on targets in the central nervous system.
Some drugs are used off-label. Exenatide (Byetta, Bydureon) is approved for type 2 diabetes in children 10 to 17, and studies found significant weight loss in children 9 to 16 with obesity who took it. Metformin, a daily pill for type 2 diabetes, produced significant weight reductions in children with obesity aged 10 and up in studies, and a 2021 AAP report found it was the most commonly prescribed weight-loss drug among children and adolescents. Topiramate, an FDA-approved seizure medication, led to lower BMI and weight over 16 weeks in children 12 and up with severe obesity.
The strongest evidence cited involves Wegovy. A study in the New England Journal of Medicine found that adolescents aged 12 to 17 who took it with counseling lost an average of 14.7% of their body weight, while those on placebo gained 2.7%. Aaron Kelly, co-director of the University of Minnesota's Center for Pediatric Obesity Medicine, told NBC that over 40% of participants cut their starting BMI by 20%. A 17-year-old participant told NBC she lost 70 pounds during the trial.
Two things to watch: the academy's forthcoming prevention statement, and whether growing prescribing deepens the Wegovy shortage.
Citações Notáveis
The guidelines aim to help patients make sustainable changes in lifestyle, behavior or environment.— Dr. Sandra Hassink, AAP guideline author
Quer a matéria completa?
Leia o original em Forbes ↗
Health & Medicine